Long-term outcome of acquired transthyretin amyloidosis

Acquired ATTR amyloidosis frequently develops in long-term DLT recipients. Although tafamidis stabilizes clinical manifestations in most patients, it may not completely prevent disease progression in some cases. Further long-term evaluation is needed to determine optimal treatment strategies, including siRNA therapy.